Intercell aims in developing a new generation of chemically defined vaccines for preventing and treating infectious diseases including chronic infections and cancer. The company’s most advanced products are therapeutic vaccines for hepatitis C, tuberculosis, melanoma and bladder cancer. Intercell’s work is based on two technological programs, the Antigen Identification Program (AIP) and the Vaccine Improvement Program (VIP). The company is developing prophylactic and therapeutic vaccines called ‘smart vaccines’ having disease specific antigens and the Intercell Immunizers.